Archive: 15/04/2021

untitled9

CNYBAC Client Quadrant Biosciences Receives FDA Designation as a "Breakthrough Device" for Clarifi ASD

Provided by Richard Uhlig, CEO Quadrant BiosciencesFDA has designated Quadrant Biosciences Clarifi ASD Test a "Breakthrough Device.”  Clarifi ASD is the world's first molecular test to facilitate the early diagnosis of Autism Spectrum Disorder and represents the most recent evolution of the pione...
CNYBAC Client Quadrant Biosciences Receives FDA Designation as a "Breakthrough Device" for Clarifi ASD